Floatz logo

Therapeutic Allogeneic Lymphocytes

Plasma Cell Myeloma

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityCell therapyPhase 2Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
89/ 100

Competitive context

475 Active assets in the Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
Hyaluronidase Fihj
Massachusetts General Hospital
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB
Vincristine Sulfate
Roswell Park Cancer Institute
Phase 3BBB
Cyclosporin A
Seoul National University Hospital
Phase 3BBB
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
University of Birmingham
Phase 4BBB

View all 50 →

Same molecule, other indications

Therapeutic Allogeneic Lymphocytes is also rated in:

chronic myeloid leukemiaDormant
BBB
Indicative · Phase 2
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative · Phase 2
70 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative · Phase 2
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →